These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35040385)

  • 1. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
    Zhang LY; Shen ZX; Guo L
    Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
    Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
    BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RBM8A Depletion Decreases the Cisplatin Resistance and Represses the Proliferation and Metastasis of Breast Cancer Cells via AKT/mTOR Pathway.
    Song T; Zhang H
    Breast J; 2022; 2022():4576789. PubMed ID: 36105365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
    Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
    Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
    Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
    Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Gu Y; Fei Z; Zhu R
    Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.
    Wang L; Yang X; Zhou F; Sun X; Li S
    Bioengineered; 2022 Mar; 13(3):7197-7208. PubMed ID: 35263216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
    Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
    Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
    Yoon H; Min JK; Lee DG; Kim DG; Koh SS; Hong HJ
    Cancer Lett; 2012 Mar; 316(1):70-6. PubMed ID: 22088438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b.
    Zhang X; Gu G; Li X; Zhang C
    Cell Cycle; 2020 Oct; 19(19):2530-2537. PubMed ID: 32892697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.